Trial Profile

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Sep 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donepezil (Primary)
Indications Dementia; Parkinson's disease
Focus Therapeutic Use
Sponsors Eisai Inc

Most Recent Events

08 Mar 2012 Actual patient number of the extension trial (NCT01327859) is 357.
08 Mar 2012 Actual patient number of the extension trial (NCT01327859) is 357.
08 Mar 2012 Planned end date of the extension trial (NCT01327859) is Jul 2006.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com